Dr. Steven Theriault reports

CYTOPHAGE UPDATE ON UPCOMING PRODUCT FOR EGG PRODUCTION IN CANADA

Cytophage Technologies Ltd. has completed research and development of its OvaPhage product, and is preparing to conduct field trials in Canada as a final step before commercialization. Cytophage has been in longstanding discussions with Canadian industry leaders who have sought alternatives to the currently available disinfectant products used in egg production. As a result, Cytophage has developed OvaPhage, its next product in the FarmPhage line. OvaPhage is a bacteriophage product that will address bacteria such as salmonella, escherichia and shigella on the surface of eggs. OvaPhage is a disinfectant bacteriophage product that, in laboratory studies, reduces 90 per cent of bacterial load on egg shells. OvaPhage is also environmentally friendly, non-toxic and does not damage the cuticle of the egg.

Cytophage developed OvaPhage based on its proprietary bacteriophage technology, and has tested it in its laboratories over the past nine months. Cytophage is now preparing for field trials, which will involve testing the product in poultry barns. OvaPhage will be sprayed on the eggs using the existing closed spray systems available in poultry barns. The company's national poultry adviser has indicated that Canadian egg producers would welcome new products that will decrease spoilage and increase revenues, while not requiring new application processes.

To facilitate this step, an experimental studies certificate application is being prepared for submission to the Canadian Food Inspection Agency. An application for regulatory approval in the United States has been submitted and a similar regulatory approval submission for Canada is currently being developed. Upon completion of field testing and regulatory approvals, the company expects to commence commercialization of OvaPhage across Canada.

"OvaPhage is one of several product developments that Cytophage aims to commercialize in 2024 with our proprietary bacteriophage technology," said Dr. Steven Theriault, chief executive officer of Cytophage. "Canada is a global leader in maximizing egg production. We believe that the successful field testing and commercialization of OvaPhage in Canada will strongly position the product for distribution across the globe. We look forward to providing continued updates as to additional bacteriophage products, and applications in both animal health and human health."

About Cytophage Technologies Ltd.

Cytophage is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization. Committed to addressing the global challenge of antibiotic resistance, Cytophage advances innovative products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health and food security.

We seek Safe Harbor.